Literature DB >> 22484021

The functional variant V433M of the CYP4F2 and the metabolic syndrome in Swedes.

Cristiano Fava1, Martina Montagnana, Elisa Danese, Marketa Sjögren, Peter Almgren, Gian Cesare Guidi, Bo Hedblad, Gunnar Engström, Pietro Minuz, Olle Melander.   

Abstract

BACKGROUND AND AIM: The genetic basis of Metabolic syndrome (MetS) is largely unknown but a link with salt sensitivity is recognized. The cytochrome P450 isoform 4F2 (CYP4F2) is involved in renal production of 20-hydroxyeicosatethraenoic acid (20-HETE), a natriuretic substance associated with salt sensitivity. The same enzyme is implicated in ω-hydroxylation of very long and medium chain fatty acids in the liver suggesting its possible influence on gluco-metabolic components of MetS. The aim of the present study was to evaluate the effect of CYP4F2 V433M, a functional polymorphism previously associated with hypertension via renal salt reabsorption, on the individual components of MetS and MetS itself.
METHODS: The polymorphism was genotyped in the cardiovascular cohort of the Malmö Diet and Cancer (MDC-CVA) study and successively in the Malmö Preventive Project (MPP) cohort. Different definitions of the MetS were applied.
RESULTS: In the MDC-CVA, male, but not female, CYP4F2 M433 carriers had significantly higher levels of waist, triglycerides, BP and a composite sum of MetS phenotypes (MetS score) beside lower HDL-cholesterol respect to V-homozygotes. MetS, as defined in the ATPIII and the AHA/NHLBI definitions, was more prevalent in M-carriers with respect to V-homozygotes. In the MPP cohort, significant association was detectable only for triglycerides at baseline and for Diastolic BP at reinvestigation in male M-carriers.
CONCLUSION: The initial positive association of the CYP4F2 V433M polymorphism with components of MetS and MetS itself, found in MDC-CVA, was partially denied in another large cohort. The first association either could be due to a false positive result or alternatively, different genetic background or population stratification could have hidden the effect of the polymorphism in the replication cohort.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484021     DOI: 10.1016/j.prostaglandins.2012.03.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  11 in total

Review 1.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

Review 2.  Mechanisms for the prevention of vitamin E excess.

Authors:  Maret G Traber
Journal:  J Lipid Res       Date:  2013-03-15       Impact factor: 5.922

3.  Elevated 20-HETE impairs coronary collateral growth in metabolic syndrome via endothelial dysfunction.

Authors:  Gregory Joseph; Amanda Soler; Rebecca Hutcheson; Ian Hunter; Chastity Bradford; Brenda Hutcheson; Katherine H Gotlinger; Houli Jiang; John R Falck; Spencer Proctor; Michal Laniado Schwartzman; Petra Rocic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-23       Impact factor: 4.733

Review 4.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

5.  High-fat diet-induced obesity and insulin resistance in CYP4a14-/- mice is mediated by 20-HETE.

Authors:  Ankit Gilani; Varunkumar Pandey; Victor Garcia; Kevin Agostinucci; Shailendra P Singh; Joseph Schragenheim; Lars Bellner; John R Falck; Mahesh P Paudyal; Jorge H Capdevila; Nader G Abraham; Michal Laniado Schwartzman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-08       Impact factor: 3.619

6.  Androgen-sensitive hypertension associates with upregulated vascular CYP4A12-20-HETE synthase.

Authors:  Cheng-Chia Wu; Shaojun Mei; Jennifer Cheng; Yan Ding; Adam Weidenhammer; Victor Garcia; Fan Zhang; Katherine Gotlinger; Vijaya L Manthati; John R Falck; Jorge H Capdevila; Michal L Schwartzman
Journal:  J Am Soc Nephrol       Date:  2013-05-02       Impact factor: 10.121

7.  Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.

Authors:  Shaminie Athinarayanan; Rongrong Wei; Min Zhang; Shaochun Bai; Maret G Traber; Katherine Yates; Oscar W Cummings; Jean Molleston; Wanqing Liu; Naga Chalasani
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

8.  CYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese population.

Authors:  Changqing Yu; Qingkai Yan; Chunjiang Fu; Weibin Shi; Hongyong Wang; Chunyu Zeng; Xukai Wang
Journal:  Lipids Health Dis       Date:  2014-05-20       Impact factor: 3.876

9.  CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration.

Authors:  Ruta Sakiene; Alvita Vilkeviciute; Loresa Kriauciuniene; Vilma Jurate Balciuniene; Dovile Buteikiene; Goda Miniauskiene; Rasa Liutkeviciene
Journal:  Adv Med       Date:  2016-08-29

10.  Genetic determinants of growth hormone and GH-related phenotypes.

Authors:  Erik Hallengren; Peter Almgren; Malin Svensson; Widet Gallo; Gunnar Engström; Margaretha Persson; Olle Melander
Journal:  BMC Genomics       Date:  2017-10-24       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.